Aktie A006620 DONGKOO BIO & PHARMA CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen DongKoo Bio & Pharma Co., Ltd.

Aktien

A006620

KR7006620009

A006620

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 24.06.2024 		% 5 Tage % 1. Jan.
6’870 KRW -2.69% Intraday Chart für DongKoo Bio & Pharma Co., Ltd. -3.24% +21.38%
2023 DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:A006620) gibt einen Aktienrückkauf im Wert von 2.000 Millionen KRW bekannt. CI
2023 DongKoo Bio&Pharma Co., Ltd. genehmigt einen Rückkaufplan. CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on November 2, 2023, has expired with 321,701 shares, representing 1.17% for KRW 1,998.73 million.
Qurient Co., Ltd. announced that it expects to receive KRW 13.499998256 billion in funding from DongKoo Bio & Pharma Co., Ltd. and another investor
OTOM Co., Ltd. announced that it has received KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.
HDT Co., Ltd announced that it expects to receive KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.
DongKoo Bio & Pharma Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.
DongKoo Bio&Pharma Co., Ltd. authorizes a Buyback Plan.
DongKoo Bio & Pharma Co., Ltd.(KOSDAQ:A006620) dropped from S&P Global BMI Index
DongKoo Bio & Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
HLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on January 28, 2022, has expired with 416,327 shares, representing 1.49% for KRW 2,995.1 million.
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on October 14, 2021.
DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback announced on October 14, 2021, has expired with 251,612 shares, representing 0.89% for KRW 1,997.79 million.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A006620 Aktie
  4. Nachrichten DongKoo Bio & Pharma Co., Ltd.
  5. Andere Sprachen